CD30 is under clinical development by Wuhan Bio-Raid Biotechnology and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase I drugs for Peripheral T-Cell Lymphomas (PTCL) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD30’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of adult T-cell leukemia/lymphoma, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, NK/T-cell lymphoma, peripheral T-cell lymphoma, enteropathy-associated T cell lymphoma, Burkitt lymphoma, Hodgkin lymphoma, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma and mycosis fungoides. It is administered as an infusion through parenteral route and intravenous route. The therapeutic candidate constitutes autologous T cells genetically modified by lentivirus vector encoding 3rd generation anti-CD30 CAR. It acts by targeting tumor cells expressing CD30.
Wuhan Bio-Raid Biotechnology overview
Wuhan Bio-Raid Biotechnology is a developer of CAR-T cell immunotherapy that promotes cellular immunotherapy technology to clinical application. The company is headquartered in China.
For a complete picture of CD30’s drug-specific PTSR and LoA scores, buy the report here.